Enzymes play a crucial role in the metabolic activities of all organisms, whether animal, human, plant, or microbial.

According to our new research study on “Organoids Market to 2027 – Global Analysis and Forecast – by Type, Application, and Source,” the organoids market was valued at US$ 689.47 million in 2019 and is projected to reach US$ 3,420.40 million by 2027; it is expected to grow at a CAGR of 22.1% during 2020–2027. The growth of the market is attributed to increasing demand for tumor modelling and biobanking, escalating adoption of personalized drugs, and growing focus on developing alternatives for animal testing models. However, issues related to the incorporation of organoids into existing workflows and dearth of skilled professionals hinder the growth of the market. `

Organoids are tiny, self-organized three-dimensional tissue cultures that are derived from stem cells. Such cultures can be crafted to replicate much of the complexity of an organ, or to express selected aspects of it like producing only certain types of cells. Organoids grow from stem cells—cells that can divide indefinitely and produce different types of cells as part of their progeny. Organoids can range in size from less than the width of a hair to five millimeters. 

The scope of the organoids market includes type, application, source, and region. The organoids market is analyzed based on regions, such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the organoids market emphasizing on various parameters, such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe. 

Get sample PDF Copy of Organoids Market study at: https://www.theinsightpartners.com/sample/TIPRE00017616/

Organoids Market Competitive analysis and Landscape

STEMCELL Technologies, Inc, Cellesce Ltd., Hubrecht Organoid Technology, Definigen, 3Dnamics, Inc., Organoid Therapeutics, PeproTech, Inc., Thermo Fisher Scientific, Corning Incorporated (Life Sciences) and Merck KGgA. are among the key companies operating in the global organoids market. Leading players are focusing on the expansion and diversification of their market presence, and acquisition of new customer base, thereby tapping prevailing business opportunities.

Increasing Adoption of Personalized Drugs

Personalized medicine is a growing area of treatment that relies on specific drug delivery and dosing. As per a study published by Personalized Medicine Coalition (PMC), in 2005, personalized medicines accounted for only 5% of the new FDA approved molecular entities; whereas, they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years.

The implementation of organoids to create personalized drug therapies is providing some exciting opportunities for improving patient care. Recent research has highlighted that more than 50% of consumers express an interest in purchasing customized products or services. This demand would require adaptation by multiple industries, including the pharmaceutical sector. Since the Precision Medicine’s Initiative was released in the US in 2015, pharmaceutical research has been pursuing the development of more tailored treatments in an attempt to make medicines safer and effective.

Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.

Organoids Market: Segmental Overview

In terms of type, the kidney organoids segment is anticipated to register the highest CAGR in the organoids market during the forecast period. Kidney organoids, derived from human pluripotent stem cells, have the potential to assist the drug development process. An international team of researchers—led by Nanyang Technological University Singapore (NTU Singapore)—has grown “miniature kidneys” in laboratory, which could be used to better understand the mechanism of development of renal diseases in individual patients. The mini kidneys, i.e., kidney organoids, were grown in vitro from skin cells derived from a single patient who had polycystic kidney disease, one of the most common inherited causes of kidney failure in adults. In terms of application, the developmental biology disease segment accounted for more than 29% share in global organoids market in 2019. In terms of source, the market for the pluripotent stem cells segment is anticipated to grow at a higher CAGR during the forecast period.

In October 2019, Corning Incorporated launched two new products—Elplasia and Matrigel—to its organoid culture portfolio to provide new solutions to support spheroid and organoid culture models. Elplasia, a 3D cell culture microplate, features a microcavity technology that enables high-volume spheroid formation, culture, and analysis. The Matrigel matrix for organoid culture is optimized to support organoid growth and differentiation.

Buy Complete Report of Organoids Market study at: https://www.theinsightpartners.com/buy/TIPRE00017616/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Back to news